Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0487-0111 in Heart Failure with Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07567001Phase 3Recruiting
- Sponsor
- Novo Nordisk
- Start
- May 2026
- Primary completion
- Jul 2029
- Countries
- 27
01
Overview
A Phase 3 trial of amycretin in heart failure (HF), obesity, sponsored by Novo Nordisk. Started May 2026; status: recruiting.
02
Drugs
amycretin
03
Conditions
heart failure (HF)obesity
Beyond the preview
Go deeper on NCT07567001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07567001.